A Dutch National Study on behalf of the Center for Personalized Cancer Treatment (CPCT) to Facilitate Patient Access to Commercially Available, Targeted Anti-cancer Drugs to determine the Potential Efficacy in Treatment of Advanced Cancers with a Known Molecular Profile: The Drug Rediscovery Protocol (DRUP trial)

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-509152-33-00

Acronym

M15DRU

Enrollment

3000

Registered

2024-03-26

Start date

2016-07-25

Completion date

Unknown

Last updated

2025-12-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced solid tumor, Non-Hodgkin lymphoma, T-cell prolymphocytic leukemia, Multiple myeloma

Brief summary

Percentage of patients that are treated based on their molecular tumor profile, Objective tumor response, Disease control, defined as Stable Disease (SD) at 16 weeks after treatment initiation, Treatment-related grade≥3 and serious adverse events

Detailed description

Progression-free and overall survival, Duration of treatment on study (time on drug)

Interventions

DRUGZejula 100 mg film-coated tablets

DRUGZelboraf 240 mg film-coated tablets

DRUGInlyta 1 mg film-coated tablets

DRUGVerzenios 50 mg film-coated tablets

DRUGLorviqua 100 mg film-coated tablets

DRUGTarceva 100 mg film-coated tablets

DRUGTasigna 200 mg hard capsules

DRUGStivarga 40 mg film-coated tablets

DRUGTafinlar 75 mg hard capsules

DRUGZejula 100 mg hard capsules

DRUGTibsovo 250 mg film-coated tablets

DRUGHerceptin 150 mg powder for concentrate for solution for infusion

DRUGTEPMETKO 225 mg film-coated tablets

DRUGYERVOY 5 mg/ml concentrate for solution for infusion

DRUGPiqray 50 mg and 200 mg film-coated tablets

DRUGTasigna 150 mg hard capsules

DRUGSutent 12.5 mg hard capsules

DRUGLorviqua 25 mg film-coated tablets

DRUGTecentriq 1 200 mg concentrate for solution for infusion

DRUGOPDIVO 10 mg/mL concentrate for solution for infusion.

DRUGXALKORI 200 mg hard capsules

DRUGVizimpro 15 mg film-coated tablets

DRUGVizimpro 30 mg film-coated tablets

DRUGRubraca 250 mg film-coated tablets

DRUGLynparza 150 mg film-coated tablets

DRUGTarceva 150 mg film-coated tablets

DRUGPerjeta 420 mg concentrate for solution for infusion

DRUGRetsevmo 40 mg hard capsules

DRUGPemazyre 4.5 mg tablets

DRUGLENVIMA 10 mg hard capsules

DRUGJNJ-61186372

DRUGVectibix 20 mg/ml concentrate for solution for infusion

DRUGRubraca 200 mg film-coated tablets

DRUGCABOMETYX 60 mg film-coated tablets

DRUGTalzenna 0.25 mg hard capsules

DRUGJNJ-42756493

DRUGAvastin 25 mg/ml concentrate for solution for infusion.

DRUGErivedge 150 mg hard capsules

DRUGIMFINZI 50 mg/mL concentrate for solution for infusion.

DRUGMekinist 0.5 mg film-coated tablets

DRUGRetsevmo 80 mg hard capsules

DRUGKEYTRUDA 25 mg/mL concentrate for solution for infusion

DRUGXALKORI 250 mg hard capsules

DRUGRozlytrek 100 mg hard capsules

DRUGPiqray 150 mg film-coated tablets

DRUGTarceva 25 mg film-coated tablets

DRUGCABOMETYX 20 mg film-coated tablets

DRUGInlyta 5 mg film-coated tablets

DRUGMekinist 2 mg film-coated tablets

DRUGRubraca 300 mg film-coated tablets

DRUGCotellic 20 mg film-coated tablets

DRUGLynparza 100 mg film-coated tablets

DRUGRozlytrek 200 mg hard capsules

DRUGTalzenna 1 mg hard capsules

DRUGSutent 25 mg hard capsules

DRUGAlecensa 150 mg hard capsules

DRUGLENVIMA 4 mg hard capsules

DRUGTafinlar 50 mg hard capsules

DRUGVizimpro 45 mg film-coated tablets

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Percentage of patients that are treated based on their molecular tumor profile, Objective tumor response, Disease control, defined as Stable Disease (SD) at 16 weeks after treatment initiation, Treatment-related grade≥3 and serious adverse events	—

Secondary

Measure	Time frame
Progression-free and overall survival, Duration of treatment on study (time on drug)	—

Countries

Netherlands

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026